[
  {
    "ts": null,
    "headline": "Eli Lilly And These AI Plays Lead 5 Stocks Near Buy Points",
    "summary": "Eli Lilly, the weight-loss drug heavyweight, joins AI stocks CrowdStrike Holdings and Semtech on this weekend's watchlist of five stocks near buy points.  CrowdStrike is a leader in the emerging area of AI-driven security, while Semtech's data-center chips facilitate high performance with low power consumption.  Lilly has a 99 IBD Composite Rating out of a possible 99, according to IBD Stock Checkup.",
    "url": "https://finnhub.io/api/news?id=6278e2cf73cb241bcd60705dd0f1358b9680b025b2edbf4e2eba8a0d2ddc807b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762620645,
      "headline": "Eli Lilly And These AI Plays Lead 5 Stocks Near Buy Points",
      "id": 137384460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, the weight-loss drug heavyweight, joins AI stocks CrowdStrike Holdings and Semtech on this weekend's watchlist of five stocks near buy points.  CrowdStrike is a leader in the emerging area of AI-driven security, while Semtech's data-center chips facilitate high performance with low power consumption.  Lilly has a 99 IBD Composite Rating out of a possible 99, according to IBD Stock Checkup.",
      "url": "https://finnhub.io/api/news?id=6278e2cf73cb241bcd60705dd0f1358b9680b025b2edbf4e2eba8a0d2ddc807b"
    }
  },
  {
    "ts": null,
    "headline": "This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy",
    "summary": "The stock didn't stay down for too long.",
    "url": "https://finnhub.io/api/news?id=b6692c9cec9d2347eb8d13a47433efbec99cbeb26f0c984c273f10f759d3d4da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762615800,
      "headline": "This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy",
      "id": 137384527,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The stock didn't stay down for too long.",
      "url": "https://finnhub.io/api/news?id=b6692c9cec9d2347eb8d13a47433efbec99cbeb26f0c984c273f10f759d3d4da"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits",
    "summary": "STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race. Metsera accepted a sweetened offer from Pfizer late Friday (November 7). It cited U.S. antitrust risks in Novo's bid that it had previously called superior. Novo said in a statement that it believed its offer structure was \"compliant with antitrust laws.\"Metsera’s drugs are projected to reach $5 billion in peak sales.And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves. It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…And that it would \"continue to assess opportunities for business development and acquisitions”.Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.",
    "url": "https://finnhub.io/api/news?id=74f4c9d163e2748e85a30cc4a3a272dff743993d2f722a0ac1c45e9bcb965784",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762607874,
      "headline": "Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits",
      "id": 137384528,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race. Metsera accepted a sweetened offer from Pfizer late Friday (November 7). It cited U.S. antitrust risks in Novo's bid that it had previously called superior. Novo said in a statement that it believed its offer structure was \"compliant with antitrust laws.\"Metsera’s drugs are projected to reach $5 billion in peak sales.And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves. It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…And that it would \"continue to assess opportunities for business development and acquisitions”.Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.",
      "url": "https://finnhub.io/api/news?id=74f4c9d163e2748e85a30cc4a3a272dff743993d2f722a0ac1c45e9bcb965784"
    }
  },
  {
    "ts": null,
    "headline": "Cisco, Walt Disney To Report Earnings Next Week While U.S. Shutdown Drags On",
    "summary": "Stay ahead with Wall Street Week Ahead: get key market previews, earnings reports, dividend alerts, and insights on upcoming economic events.",
    "url": "https://finnhub.io/api/news?id=8c7a8a31310ec0d491f7458a4829687876cc6b1fbfd02adcf0bad5a5ed9e419c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762599600,
      "headline": "Cisco, Walt Disney To Report Earnings Next Week While U.S. Shutdown Drags On",
      "id": 137379367,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Stay ahead with Wall Street Week Ahead: get key market previews, earnings reports, dividend alerts, and insights on upcoming economic events.",
      "url": "https://finnhub.io/api/news?id=8c7a8a31310ec0d491f7458a4829687876cc6b1fbfd02adcf0bad5a5ed9e419c"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030",
    "summary": "It could become the first trillion-dollar pharmaceutical company in the process.",
    "url": "https://finnhub.io/api/news?id=2b2db5a3d718ee193ec8467a6865a6293f9239ead275176995f3ab4057ee7406",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762596600,
      "headline": "Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030",
      "id": 137378306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It could become the first trillion-dollar pharmaceutical company in the process.",
      "url": "https://finnhub.io/api/news?id=2b2db5a3d718ee193ec8467a6865a6293f9239ead275176995f3ab4057ee7406"
    }
  },
  {
    "ts": null,
    "headline": "SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly",
    "summary": "SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company (\"Lilly\"). The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio's proprietary tissue selective delivery technology, LEAD™ (Ligand and Enhancer Assisted Delivery).",
    "url": "https://finnhub.io/api/news?id=44a0cd666342f5c8c767dc7abc9dd9f141e55acd6f89a526f3224abb8b6f0da7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762596000,
      "headline": "SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly",
      "id": 137378307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company (\"Lilly\"). The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio's proprietary tissue selective delivery technology, LEAD™ (Ligand and Enhancer Assisted Delivery).",
      "url": "https://finnhub.io/api/news?id=44a0cd666342f5c8c767dc7abc9dd9f141e55acd6f89a526f3224abb8b6f0da7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Breakout Is Here - Growing GLP-1 Market Share",
    "summary": "LLY's Mounjaro and Zepbound deliver accelerated weight loss rates compared to NVO's Wegovy, which perhaps explains the former's triple digits GLP-1 revenue...",
    "url": "https://finnhub.io/api/news?id=9b77854364f78ab6a74fdb303ab0794a492be903ec8feebebc05752653e71a4c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762593300,
      "headline": "Eli Lilly's Breakout Is Here - Growing GLP-1 Market Share",
      "id": 137378974,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1271085883/image_1271085883.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "LLY's Mounjaro and Zepbound deliver accelerated weight loss rates compared to NVO's Wegovy, which perhaps explains the former's triple digits GLP-1 revenue...",
      "url": "https://finnhub.io/api/news?id=9b77854364f78ab6a74fdb303ab0794a492be903ec8feebebc05752653e71a4c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.",
    "summary": "Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.",
    "url": "https://finnhub.io/api/news?id=0c784885dca203165d8ad238e3398bfcffcb28b48b9bc1f0c15615881646f2cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762591500,
      "headline": "Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors.",
      "id": 137378308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.",
      "url": "https://finnhub.io/api/news?id=0c784885dca203165d8ad238e3398bfcffcb28b48b9bc1f0c15615881646f2cf"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says “Look, in the End, There’s Eli Lilly and There’s Everybody Else”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer mentioned the stock during the episode and commented: “I do believe that there are very few biotechs that I really want to buy right now because they’re so picked over. Look, in the end, there’s Eli Lilly and […]",
    "url": "https://finnhub.io/api/news?id=9f0e2aa304cdfdacb027c39312caf151022c9e5229519e05dc5db0f36fd60c06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762574815,
      "headline": "Jim Cramer Says “Look, in the End, There’s Eli Lilly and There’s Everybody Else”",
      "id": 137378309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer mentioned the stock during the episode and commented: “I do believe that there are very few biotechs that I really want to buy right now because they’re so picked over. Look, in the end, there’s Eli Lilly and […]",
      "url": "https://finnhub.io/api/news?id=9f0e2aa304cdfdacb027c39312caf151022c9e5229519e05dc5db0f36fd60c06"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of November 9",
    "summary": "Get the latest weekly updates on dividend changes, ex-dividend and pay dates for Dividend Champions, Contenders, and Challengers.",
    "url": "https://finnhub.io/api/news?id=0f24cb5e688ce530a1a3feef456bd575a4ec37a9f09b01feab5a82b5eee9fb0e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762560224,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of November 9",
      "id": 137376571,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Get the latest weekly updates on dividend changes, ex-dividend and pay dates for Dividend Champions, Contenders, and Challengers.",
      "url": "https://finnhub.io/api/news?id=0f24cb5e688ce530a1a3feef456bd575a4ec37a9f09b01feab5a82b5eee9fb0e"
    }
  }
]